Table 8. Reporting rates of suspected myocarditis following Pfizer-BioNTech and Moderna COVID-19 vaccines in Japan, by age and sex (as of 5 December 2021).
| Age group (years) |
Pfizer-BioNTech (number of events per 1 million doses) |
Moderna (number of events per 1 million doses) |
||||||
|---|---|---|---|---|---|---|---|---|
| Both doses | 2nd dose | Both doses | 2nd dose | |||||
| Male | Female | Male | Female | Male | Female | Male | Female | |
|
10–14
|
13.4 |
1.5 |
21.6 |
1.1 |
42.3 |
0 |
89.8 |
0 |
| 15–19 | 12.9 | 2.5 | 21.9 | 1.7 | 50.6 | 1.3 | 86.5 | 2.5 |
| 20–24 | 8.2 | 0.6 | 12.2 | 0 | 27.9 | 1.1 | 51.9 | 1.1 |
| 25–29 | 6.0 | 0.9 | 10.2 | 1.2 | 19.7 | 1.4 | 34.7 | 2.9 |
| 30–34 | 2.4 | 0.8 | 3.0 | 0 | 5.9 | 1.6 | 10.9 | 0 |
| 35–39 | 1.3 | 1.5 | 2.0 | 0.9 | 1.5 | 1.5 | 2.0 | 1.6 |
| 40–44 | 2.1 | 0.9 | 3.8 | 0.4 | 3.0 | 1.5 | 4.0 | 1.5 |
| 45–49 | 0.8 | 0.6 | 0.7 | 0.6 | 2.6 | 2.6 | 4.4 | 2.6 |
| 50–54 | 0.8 | 0.9 | 1.0 | 0.3 | 0.5 | 2.2 | 1.0 | 3.0 |
| 55–59 | 1.1 | 0.3 | 1.1 | 0.7 | 1.3 | 0 | 2.6 | 0 |
| 60–64 | 0.4 | 0.8 | 0.7 | 1.3 | 0 | 0 | 0 | 0 |
| 65–69 | 0.9 | 0.4 | 0.6 | 0 | 2.1 | 2.9 | 4.3 | 0 |
| 70–74 | 0.4 | 0.8 | 0 | 0.2 | 0 | 0 | 0 | 0 |
| 75–79 | 0.7 | 0.1 | 0.4 | 0 | 0 | 0 | 0 | 0 |
| ≥ 80 | 1.0 | 0.9 | 0.8 | 0.9 | 0 | 0 | 0 | 0 |
Data include Brighton Collaboration level 1–5 cases.
Source: Data are reproduced with permission from the Ministry of Health, Labour and Welfare, Japan. (15)